Hematologic effects of phenytoin therapy during pregnancy
- PMID: 662246
Hematologic effects of phenytoin therapy during pregnancy
Abstract
Serum folate and plasma phenytoin concentrations were measured in 10 epileptic gravidas who did not receive folate supplementation. Mean serum folate concentration averaged 5.0 ng/ml during the second and third trimesters of pregnancy but significantly decreased to 2.9 ng/ml during nonpregnant evaluation 1 to 12 months following delivery. No patient exhibited anemia or macrocytosis suggestive of cellular folate deficiency either during or following pregnancy. Although phenytoin dosage remained relatively constant, plasma phenytoin concentrations during pregnancy were significantly lower than nonpregnant concentrations. The improvement in folate status observed during pregnancy may be related to lowered plasma phenytoin concentrations.
Similar articles
-
[Decrease of folic acid and cognitive alterations in patients with epilepsy treated with phenytoin or carbamazepine, pilot study].Rev Invest Clin. 2005 Jul-Aug;57(4):522-31. Rev Invest Clin. 2005. PMID: 16315636 Clinical Trial. Spanish.
-
Epilepsy and pregnancy. Serum thyroxine levels during phenytoin therapy.Obstet Gynecol. 1979 Mar;53(3):344-7. Obstet Gynecol. 1979. PMID: 424107
-
Phenytoin-folic acid interaction: a lesson to be learned.Clin Neuropharmacol. 1999 Sep-Oct;22(5):268-72. Clin Neuropharmacol. 1999. PMID: 10516876
-
Mechanisms of teratogenesis: folic acid and antiepileptic therapy.Neurology. 1992 Apr;42(4 Suppl 5):32-42. Neurology. 1992. PMID: 1574174 Review.
-
Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation.Epilepsia. 2003;44 Suppl 3:33-40. Epilepsia. 2003. PMID: 12790884 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources